Innovative Therapies Expansion Glaukos Corporation is developing innovative therapies for glaucoma treatment, showcasing a commitment to advancing medical care. This focus on novel treatments presents a prime opportunity for sales growth and collaboration within the ophthalmic market.
Product Launches & Partnerships Recent launches like iStent Infinite and partnerships with Ripple Therapeutics Corporation and Nicox Group signal a proactive approach to product development and market expansion. Leveraging these new products and collaborations can open doors for increased sales and market presence.
Investment Attractiveness With notable investments from firms like Intech Investment Management LLC, Glaukos Corporation's potential for growth and innovation is recognized in the financial realm. This financial back-up can boost confidence for potential clients and investors, providing a solid foundation for sales activities.
Advanced Technological Offerings The introduction of technologies like iDose TRIO and iDose technology showcases Glaukos' commitment to advanced medical solutions. Highlighting these cutting-edge technological offerings can present unique selling points and competitive advantages in engaging with healthcare professionals and institutions.
Industry Recognition & Expansion Being a front-runner in developing glaucoma therapies and receiving industry recognition for innovations positions Glaukos Corporation as a prime player in the ophthalmic sector. Leveraging this industry position and expanding market reach can lead to increased sales opportunities and partnerships.
860
$100M$1B
501$100M$1B
1K$100M$1B
26K$1B
69$10MGlaukos Corporation uses 8 technology products and services including Facebook Pixel, Google Font API, Backbone.js, and more. Explore Glaukos Corporation's tech stack below.
| Glaukos Corporation Email Formats | Percentage |
| FLast@glaukos.com | 95% |
| First.Last@glaukos.com | 3% |
| First-Last@glaukos.com | 1% |
| FirstLast@glaukos.com | 1% |
Medical Equipment ManufacturingCalifornia, United States501-1000 Employees
At Glaukos, our focus is to develop and lead the global ophthalmic market with novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases—therapies that advance the existing standard of care and enrich the lives and treatment alternatives for patients worldwide.
Company Overview
Media & News
Funding & FinancialsGlaukos Corporation has raised a total of $30M of funding over 7 rounds. Their latest funding round was raised on Feb 07, 2013 in the amount of $30M.
Glaukos Corporation's revenue is in the range of $100M$1B
Funding & FinancialsGlaukos Corporation has raised a total of $30M of funding over 7 rounds. Their latest funding round was raised on Feb 07, 2013 in the amount of $30M.
Glaukos Corporation's revenue is in the range of $100M$1B
1-888-653-2347 
support@leadiq.com